logo
Intel's new CEO explores big shift in chip manufacturing business

Intel's new CEO explores big shift in chip manufacturing business

CTV News2 days ago
Intel's new chip offers a promise of lighter PCs that can better compete with tablets. (AFP PHOTO / Robyn Beck)
SAN FRANCISCO — Intel's new chief executive is exploring a big change to its contract manufacturing business to win major customers, two people familiar with the matter told Reuters, in a potentially expensive shift from his predecessor's plans.
The new strategy for Intel's foundry business would mean offering outside customers a newer generation of technology, the people said. That next-generation chipmaking process, analysts believe, will be more competitive against Taiwan Semiconductor Manufacturing Co in trying to land major customers such as Apple or Nvidia.
Shares of Intel fell as much as five per cent on Wednesday morning on the Nasdaq.
Since taking the company's helm in March, CEO Lip-Bu Tan has moved fast to cut costs and find a new path to revive the ailing U.S. chipmaker. By June, he started voicing that a manufacturing process known as 18A, in which prior CEO Pat Gelsinger had invested heavily, was losing its appeal to new customers, said the sources, who spoke on condition of anonymity.
To put aside external sales of 18A and its variant 18A-P, manufacturing processes that have cost Intel billions of dollars to develop, the company would have to take a write-off, one of the people familiar with the matter said. Industry analysts contacted by Reuters said such a charge could amount to a loss of hundreds of millions, if not billions, of dollars.
Intel declined to comment on such 'hypothetical scenarios or market speculation.' It said the lead customer for 18A has long been Intel itself, and it aims to ramp production of its 'Panther Lake' laptop chips later in 2025, which it called the most advanced processors ever designed and manufactured in the United States.
Persuading outside clients to use Intel's factories remains key to its future. As its 18A fabrication process faced delays, rival TSMC's N2 technology has been on track for production.
Tan's preliminary answer to this challenge: focus more resources on 14A, a next-generation chipmaking process where Intel expects to have advantages over Taiwan's TSMC, the two sources said. The move is part of a play for big customers like Apple and Nvidia, which currently pay TSMC to manufacture their chips.
Tan has tasked the company with teeing up options for discussion with Intel's board when it meets as early as this month, including whether to stop marketing 18A to new clients, one of the two sources said. The board might not reach a decision on 18A until a subsequent autumn meeting in light of the matter's complexity and the enormous money at stake, the person said.
Intel declined to comment on what it called rumor. In a statement, it said: 'Lip-Bu and the executive team are committed to strengthening our roadmap, building trust with our customers, and improving our financial position for the future. We have identified clear areas of focus and will take actions needed to turn the business around.'
Last year was Intel's first unprofitable year since 1986. It posted a net loss attributable to the company of US$18.8 billion for 2024.
The Intel chief executive's deliberations show the enormous risks - and costs - under consideration to move the storied U.S. chipmaker back onto solid footing. Like Gelsinger, Tan inherited a company that had lost its manufacturing edge and fell behind on crucial technology waves of the past two decades: mobile computing and artificial intelligence.
The company is targeting high-volume production later this year for 18A with its internal chips, which are widely expected to arrive ahead of external customer orders. Meanwhile, delivering 14A in time to win major contracts is by no means certain, and Intel could choose to stick with its existing plans for 18A, one of the sources said.
Intel is tailoring 14A to key clients' needs to make it successful, the company said.
AMAZON AND MICROSOFT ON 18A
Tan's review of whether to focus clients on 14A involves the contract chipmaking portion of Intel, or foundry, which makes chips for external customers.
Regardless of a board decision, Intel will make chips via 18A in cases where its plans are already in motion, the people familiar with the matter said. This includes using 18A for Intel's in-house chips that it already designed for that manufacturing process, the people said.
Intel also will produce a relatively small volume of chips that it has guaranteed for Amazon.com AMZN.O and Microsoft MSFT.O via 18A, with deadlines that make it unrealistic to wait for the development of 14A.
Amazon and Microsoft did not immediately comment on the matter. Intel said it will deliver on its customer commitments.
Tan's overall strategy for Intel remains nascent. So far, he has updated his leadership team, bringing in new engineering talent, and he has worked to shrink what he considered bloated and slow-moving middle management.
Shifting away from selling 18A to foundry customers would represent one of his biggest moves yet.
The 18A manufacturing process includes a novel method of delivering energy to chips and a new type of transistor. Together, these enhancements were meant to let Intel match or exceed TSMC's capabilities, Intel executives have previously said.
However, according to some industry analysts, the 18A process is roughly equivalent to TSMC's so-called N3 manufacturing technology, which went into high-volume production in late 2022.
If Intel follows Tan's lead, the company would focus its foundry employees, design partners and new customers on 14A, where it hopes for a better chance to compete against TSMC.
Tan has drawn on extensive contacts and customer relationships built over decades in the chip industry to arrive at his view on 18A, the two sources said.
(Reporting by Jeffrey Dastin, Max A. Cherney and Stephen Nellis in San Francisco; Editing by Kenneth Li and Matthew Lewis)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Boeing Stock Set for a Ride as NASA Progresses in Artemis II Program
Boeing Stock Set for a Ride as NASA Progresses in Artemis II Program

Globe and Mail

time13 minutes ago

  • Globe and Mail

Boeing Stock Set for a Ride as NASA Progresses in Artemis II Program

NASA's Artemis II mission, the first crewed flight in its lunar return program, set to launch in April 2026, has reached critical milestones in recent months, reigniting investor interest in aerospace giant Boeing BA, a key contractor in the Space Launch System (SLS) program. On July 2, 2025, NASA announced on its Facebook page that the Program Specific Engineering Test for the Artemis II core stage had been completed. In early June, the Artemis II team conducted its first mission simulation to rehearse lunar science operations for the upcoming crewed mission. Earlier, in March, the integration of the Artemis II SLS core stage with its solid rocket boosters was successfully completed, which was another key milestone in preparing the rocket for launch. To this end, it is imperative to mention that the SLS rocket, designed to carry astronauts farther into space than ever before, is led by Boeing as the prime contractor for its core stage, upper stage, and avionics systems. The jet giant is currently building the core stages for all future Artemis missions. Thus, for Boeing, Artemis II represents more than just a technological triumph — it's a strategic revenue driver. With the company's Defense, Space & Security segment accounting for nearly 36% of total revenues in 2024, space programs like Artemis are key to Boeing's efforts to gain from a diversified portfolio beyond its struggling commercial aviation business and provide it with a significant financial cushion. With Artemis II on track, NASA's commitment to sustaining the Artemis program through Artemis III and beyond implies recurring revenue potential for Boeing over the long run, given its deep involvement in every SLS flight configuration. As investor interest in space stocks has been gaining increasing traction these days, the continued success of the Artemis mission should strengthen Boeing's positioning in the $500 billion global space economy and offer a promising growth vector for its shares. The potential upside reflected in BA's price target further supports this thesis. Based on short-term price targets provided by 22 analysts, the average Zacks price target for Boeing implies a 6.4% upside from its last closing price. Other Space Stocks Warrant a Look Other stocks, involved in the SLS program and Artemis missions, like Lockheed Martin LMT and L3Harris Technologies Inc. LHX, also stand to benefit from the steady progress of the Artemis II mission. Notably, Lockheed is the prime contractor involved in the construction of Orion, the spacecraft that will carry the crew of four astronauts in the Artemis II mission. In May 2025, LMT achieved a significant milestone in the development of NASA's Orion spacecraft by officially transferring it to NASA's Exploration Ground Systems team, following the completion of the spacecraft's assembly and testing. On the other hand, L3Harris is involved in the Artemis II mission through its Aerojet Rocketdyne business unit, which provides the RS-25 engines that power the SLS core stage. In May 2025, Aerojet Rocketdyne completed installation of all four RS-25 main engines on the core stage of NASA's second SLS exploration rocket, which will be used in the Artemis II mission. The Zacks Rundown for BA Shares of Boeing have risen 22% year to date compared with the industry 's growth of 22.2%. From a valuation standpoint, BA is currently trading at a forward 12-month sales multiple of 1.80X, a roughly 18.9% discount when stacked up with the industry average of 2.22X. The Zacks Consensus Estimate for BA's 2025 and 2026 sales implies a year-over-year uptick of 25.6% and 16.2%, respectively. The same for its earnings per share for 2025 has moved north over the past 60 days, while the same for 2026 has moved south. BA stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report L3Harris Technologies Inc (LHX): Free Stock Analysis Report This article originally published on Zacks Investment Research (

UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector

Globe and Mail

time13 minutes ago

  • Globe and Mail

UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector

UnitedHealth Group Incorporated UNH continues to face challenges amid a turbulent healthcare insurance landscape. The passage of the 'One Big Beautiful Bill Act' through Congress, ready for President Donald Trump's signature, threatens to significantly reduce federal Medicaid spending. According to reports, approximately 11.8 million Americans are expected to lose Medicaid coverage by 2034, with 5.2 million affected by new work requirements alone. To curb state-level Medicaid expenditures, the bill gradually limits the use of 'provider taxes' as a revenue source. However, it also allocates $50 billion in funding to support rural hospitals impacted by these cuts. While insurers like UnitedHealth and Humana Inc. HUM may encounter short-term pressure from shrinking Medicaid rolls, they could ultimately benefit as displaced members shift toward private coverage options. UnitedHealth's Medicaid membership declined 4% in 2023, 5.2% in 2024, and 1.4% in the first quarter of 2025. The proposed elimination of ACA marketplace tax credits will likely propel more people into employer-sponsored plans. Meanwhile, Medicare Advantage may gain traction, as seniors grapple with increased out-of-pocket expenses due to rollbacks in Medicare Savings Programs. UnitedHealth's Medicare Advantage enrollment rose by 8.3% in 2023, 1.9% in 2024, and 6.3% in the first quarter of 2025. Another major development shook the market as Centene Corporation CNC, a major Medicaid player, withdrew its 2025 earnings guidance late Tuesday, citing unexpected enrollment shifts and higher medical costs. The move, mirroring UnitedHealth's earlier decision, rattled the managed care sector. Centene shares witnessed massive declines following the news, and peers like UnitedHealth and Humana followed suit. Centene shares plummeted 41.2% following the announcement, dragging down peers: UnitedHealth and Humana dropped 5.4% and 5.1%, respectively, despite broader market gains driven by tech strength and encouraging jobs data. Price Performance Comparison – UNH, HUM & CNC Image Source: Zacks Investment Research UnitedHealth's Valuation and Estimates From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 12.99, up from the industry average of 11.49. UNH currently carries a Value Score of A. The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is pegged at $22.07 per share, implying a 20.2% drop from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Humana Inc. (HUM): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report This article originally published on Zacks Investment Research (

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store